•Metaplanet's CEO Simon Gerovich announced a delay in the launch of perpetual preferred shares due to regulatory and infrastructure challenges in Japan.
•Pfizer received marketing authorization from the European Commission to expand the label of its Hympavzi therapy to include adolescents across all 27 EU member states.
